Brett L. Hurst

5.8k total citations · 1 hit paper
52 papers, 2.1k citations indexed

About

Brett L. Hurst is a scholar working on Epidemiology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Brett L. Hurst has authored 52 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Epidemiology, 21 papers in Infectious Diseases and 13 papers in Molecular Biology. Recurrent topics in Brett L. Hurst's work include Respiratory viral infections research (17 papers), Influenza Virus Research Studies (16 papers) and SARS-CoV-2 and COVID-19 Research (12 papers). Brett L. Hurst is often cited by papers focused on Respiratory viral infections research (17 papers), Influenza Virus Research Studies (16 papers) and SARS-CoV-2 and COVID-19 Research (12 papers). Brett L. Hurst collaborates with scholars based in United States, Australia and Japan. Brett L. Hurst's co-authors include E. Bart Tarbet, Donald F. Smee, Chunlong Ma, Jun Wang, Yanmei Hu, Julia A. Townsend, Yu Chen, Michael T. Marty, M. Sacco and Xiujun Zhang and has published in prestigious journals such as Journal of the American Chemical Society, Nature Communications and PLoS ONE.

In The Last Decade

Brett L. Hurst

52 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

2020 616 citations Chunlong Ma, M. Sacco et al. Cell Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brett L. Hurst United States	23	1.1k	678	636	503	309	52	2.1k
E. Bart Tarbet United States	23	953 0.9×	627 0.9×	613 1.0×	639 1.3×	375 1.2×	53	2.3k
Leike Zhang China	24	1.1k 1.1×	383 0.6×	880 1.4×	304 0.6×	381 1.2×	71	2.4k
Seungtaek Kim South Korea	24	957 0.9×	363 0.5×	677 1.1×	586 1.2×	217 0.7×	75	2.4k
Yanmei Hu United States	28	1.6k 1.5×	1.3k 1.9×	1.2k 1.8×	512 1.0×	271 0.9×	78	3.3k
Egor P. Tchesnokov Canada	24	2.4k 2.2×	355 0.5×	856 1.3×	557 1.1×	163 0.5×	41	3.4k
Hai Pang China	20	1.1k 1.1×	445 0.7×	678 1.1×	236 0.5×	146 0.5×	47	2.0k
Kiira Ratia United States	24	1.8k 1.7×	839 1.2×	1.3k 2.1×	282 0.6×	712 2.3×	41	3.3k
Philip V’kovski Switzerland	14	2.1k 2.0×	294 0.4×	877 1.4×	335 0.7×	374 1.2×	18	3.1k
Annika Kratzel Switzerland	6	1.8k 1.6×	306 0.5×	835 1.3×	209 0.4×	301 1.0×	9	2.7k
Yahira M. Báez-Santos United States	11	1.2k 1.1×	619 0.9×	600 0.9×	105 0.2×	419 1.4×	12	1.8k

Countries citing papers authored by Brett L. Hurst

Since Specialization

Citations

This map shows the geographic impact of Brett L. Hurst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brett L. Hurst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brett L. Hurst more than expected).

Fields of papers citing papers by Brett L. Hurst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brett L. Hurst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brett L. Hurst. The network helps show where Brett L. Hurst may publish in the future.

Co-authorship network of co-authors of Brett L. Hurst

This figure shows the co-authorship network connecting the top 25 collaborators of Brett L. Hurst. A scholar is included among the top collaborators of Brett L. Hurst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brett L. Hurst. Brett L. Hurst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gibson, Scott, Yanan Liu, Rong Li, et al.. (2024). Differences in Susceptibility to SARS-CoV-2 Infection Among Transgenic hACE2-Hamster Founder Lines. Viruses. 16(10). 1625–1625. 2 indexed citations

Martinez-Paniagua, Melisa, Mohsen Fathi, Sujit Biswas, et al.. (2024). An intranasal nanoparticle STING agonist protects against respiratory viruses in animal models. Nature Communications. 15(1). 6053–6053. 6 indexed citations

Martinez-Paniagua, Melisa, Ali Rezvan, Xinli Liu, et al.. (2024). Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters. Nature Communications. 15(1). 6193–6193. 7 indexed citations

Lane, Thomas R., Jianing Fu, Barbara Sherry, et al.. (2023). Efficacy of an isoxazole-3-carboxamide analog of pleconaril in mouse models of Enterovirus-D68 and Coxsackie B5. Antiviral Research. 216. 105654–105654. 5 indexed citations

Honda‐Okubo, Yoshikazu, et al.. (2023). An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice. Vaccine. 41(38). 5592–5602. 3 indexed citations

Honda‐Okubo, Yoshikazu, E. Bart Tarbet, Brett L. Hurst, & Nikolai Petrovsky. (2023). An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection. Vaccine. 41(39). 5730–5741. 8 indexed citations

Słabicki, Mikołaj, J. J. Patten, Charles Zou, et al.. (2022). Anti‐SARS‐CoV‐2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID‐19 therapy. Journal of Medical Virology. 95(1). e28157–e28157. 18 indexed citations

Maio, Nunziata, Sara Cherry, D. Schultz, et al.. (2022). TEMPOL inhibits SARS-CoV-2 replication and development of lung disease in the Syrian hamster model. iScience. 25(10). 105074–105074. 11 indexed citations

Hurst, Brett L., Douglas Dickinson, & Stephen Hsu. (2021). Epigallocatechin-3-Gallate (EGCG) Inhibits SARS-CoV-2 Infection in Primate Epithelial Cells. PubMed. 5(2). 13 indexed citations

10.

Huesemann, Michael H., Scott Edmundson, Amy Sims, et al.. (2021). Viral inhibitors derived from macroalgae, microalgae, and cyanobacteria: A review of antiviral potential throughout pathogenesis. Algal Research. 57. 102331–102331. 52 indexed citations

11.

Ma, Chunlong, M. Sacco, Brett L. Hurst, et al.. (2020). Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Research. 30(8). 678–692. 616 indexed citations breakdown →

12.

Westover, Jonna B., Brady T. Hickerson, Arnaud J. Van Wettere, et al.. (2019). Vascular Leak and Hypercytokinemia Associated with Severe Fever with Thrombocytopenia Syndrome Virus Infection in Mice. Pathogens. 8(4). 158–158. 13 indexed citations

13.

Hurst, Brett L., Christopher Peterson, Arnaud J. Van Wettere, et al.. (2018). Development of a respiratory disease model for enterovirus D68 in 4-week-old mice for evaluation of antiviral therapies. Antiviral Research. 162. 61–70. 26 indexed citations

14.

Hurst, Brett L., et al.. (2018). Evaluation of antiviral therapies in respiratory and neurological disease models of Enterovirus D68 infection in mice. Virology. 526. 146–154. 34 indexed citations

15.

Hurst, Brett L., Akhilesh Kumar Shakya, Md Jasim Uddin, et al.. (2017). Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses. Antiviral Research. 141. 62–72. 96 indexed citations

16.

Smee, Donald F., et al.. (2017). Evaluation of cell viability dyes in antiviral assays with RNA viruses that exhibit different cytopathogenic properties. Journal of Virological Methods. 246. 51–57. 49 indexed citations

17.

Tarbet, E. Bart, Stephanie Hamilton, Angela Luttick, et al.. (2014). A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses. Journal of Antimicrobial Chemotherapy. 69(8). 2164–2174. 15 indexed citations

18.

Tarbet, E. Bart, et al.. (2013). In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus. Archives of Virology. 159(6). 1279–1291. 27 indexed citations

19.

Sefing, Eric J., Min‐Hui Wong, Brett L. Hurst, et al.. (2013). Vascular leak ensues a vigorous proinflammatory cytokine response to Tacaribe arenavirus infection in AG129 mice. Virology Journal. 10(1). 221–221. 6 indexed citations

20.

SMEE, D. F., et al.. (2009). Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. Journal of Antimicrobial Chemotherapy. 64(4). 741–746. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact